Total Parenteral Nutrition

Mechanical/anatomic failure (lumen unusable)

• Bowel obstruction or perforation: malignant obstruction, adhesive small bowel obstruction awaiting operation, anastomotic leak.
• High-output enterocutaneous fistula: nutrients exit before absorption; bowel rest also reduces fistula output.

Absorptive failure (surface area lost)

• Short bowel syndrome: massive resection for mesenteric ischemia, midgut volvulus, Crohn disease, or necrotizing enterocolitis in neonates. Loss of terminal ileum and the ileocecal valve predicts PN dependence.
• Mucosal disease: radiation enteritis, intestinal graft-versus-host disease, refractory sprue, microvillus inclusion disease.

Motility failure (gut intact but inert)

• Chronic intestinal pseudo-obstruction, scleroderma bowel, severe refractory gastroparesis, prolonged postoperative ileus.

Non-modifiable risk factors for TPN complications

• Extremes of age: preterm neonates are most prone to parenteral nutrition–associated liver disease.
• Duration and extent of intestinal failure; remnant bowel length and absence of the ileocecal valve.
• Baseline diabetes, cirrhosis, chronic kidney disease, malignancy, immunosuppression.

Modifiable risk factors (the ones examiners reward you for changing)

• Catheter practices: femoral site, multilumen catheters, using the TPN lumen for blood draws or other infusions, and lapses in maximal sterile barrier or chlorhexidine prep — all addressed in CDC/HICPAC intravascular catheter guidance.
• Overfeeding: excess dextrose drives hepatic steatosis, hyperglycemia, and CO2 production.
• Uncontrolled hyperglycemia, complete absence of trophic enteral feeding, and unreplaced thiamine.
• Refeeding risk factors per the ASPEN consensus: very low BMI, negligible intake for several days, alcohol use disorder, anorexia nervosa, chronic diuretic use, and low pre-treatment potassium, magnesium, or phosphate.

• Macronutrient metabolism: Carbohydrates (dextrose) provide 3.4 kcal/g and stimulate insulin secretion, driving anabolism and glucose utilization; lipids provide 9 kcal/g (IV lipid emulsions provide ~10 kcal/mL) and serve as essential fatty acid sources and energy-dense substrates; proteins (amino acids) provide 4 kcal/g and supply nitrogen for protein synthesis and gluconeogenesis during catabolic states.

• Osmolarity and vascular access: Central TPN (delivered via central catheter) can achieve higher concentrations (>900 mOsm/L) because rapid blood flow prevents phlebitis; peripheral TPN has lower osmolarity (<900 mOsm/L) to minimize thrombophlebitis risk, limiting caloric delivery and typically used only short-term.

• Metabolic sequelae of TPN: Sudden nutrient infusion triggers a "refeeding syndrome" (see complications) due to shifts in electrolyte distribution and cellular uptake; insulin-mediated shift of phosphate, potassium, and magnesium intracellularly can cause severe hypokalemia, hypophosphatemia, and hypomagnesemia with cardiac arrhythmias and respiratory failure if not anticipated and corrected.

• Loss of GI barrier function: Disuse of the intestinal mucosa leads to atrophy of enterocytes and tight junctions, compromising the intestinal barrier and increasing bacterial translocation risk; absence of enteral stimulation reduces production of secretory IgA and trophic hormones (GLP-2, cholecystokinin).

• Hepatic metabolism and lipid clearance: Continuous carbohydrate and protein infusion increases hepatic lipogenesis; impaired lipid clearance and elevated triglycerides promote TPN-associated cholestasis and can precipitate fatty infiltration of the liver.

• Indications requiring TPN: Severe malnutrition with non-functional GI tract (bowel obstruction, short bowel syndrome, severe pancreatitis, enterocutaneous fistula, radiation enteritis); inability to meet nutritional needs via enteral route despite maximum enteral support; critical illness with anticipated prolonged inability to eat (e.g., post-major surgery, mechanical ventilation, severe burns).

• Signs of nutritional failure prompting TPN: Unintentional weight loss >10% body weight, serum albumin <2.5 g/dL, prealbumin <20 mg/dL, negative nitrogen balance, prolonged inadequate oral intake (>7–10 days expected).

• Clinical context matters: In a terminally ill patient with multiorgan failure, TPN rarely improves outcomes and may burden the dying process; conversely, in a young patient with temporary bowel dysfunction, TPN can bridge to recovery or adaptation.

• Nutritional assessment: Calculate 24-hour caloric needs using Harris-Benedict equation or indirect calorimetry (preferred in critically ill); estimate protein needs (1.2–2.0 g/kg/day depending on stress state); assess renal and hepatic function to guide composition adjustments.

• Laboratory baseline and monitoring tests: Baseline electrolytes (sodium, potassium, chloride, bicarbonate), phosphate, magnesium, calcium; liver and renal function (AST, ALT, ALP, bilirubin, creatinine, BUN); blood glucose, triglycerides, albumin, prealbumin; baseline CBC to assess for anemia and infection risk.

• Continued monitoring: Daily electrolytes for first 3–5 days (especially phosphate, potassium, magnesium during refeeding); twice-weekly labs once stable; weekly liver function tests and triglycerides; blood glucose monitoring (TPN causes hyperglycemia).

• Diagnostic considerations: Differentiate need for TPN from preference—if any portion of GI tract is functional, consider enteral supplementation first; identify underlying reversible causes of GI dysfunction (e.g., medication-induced ileus, mechanical obstruction amenable to surgery).

• First-line: Central venous TPN for patients requiring long-term support or high caloric density; delivered via central catheter (PICC line, tunneled catheter, or implanted port) to minimize thrombophlebitis; typical formulation includes dextrose (200–350 g/day), amino acids (70–140 g/day providing 1.2–2.0 g/kg), lipids (20–100 g/day), electrolytes, vitamins (including fat-soluble A, D, E, K and water-soluble B complex, C), and trace elements (zinc, copper, manganese, chromium, selenium).

• Peripheral TPN: Reserved for short-term support (<2 weeks) or bridge therapy; lower osmolarity (max ~900 mOsm/L) limits caloric density; requires more frequent line changes due to higher phlebitis risk; often used when central access is contraindicated or temporarily unavailable.

• Refeeding syndrome prevention (critical): In severely malnourished or prolonged-NPO patients, start TPN at reduced rate (e.g., 50% of goal for 24–48 hours), advance slowly over 3–5 days; prophylactically replicate phosphate, potassium, and magnesium before refeeding and daily during initiation; monitor serum levels closely and correct deficits aggressively; thiamine supplementation (vitamin B1) prevents Wernicke's encephalopathy in alcoholic or chronically malnourished patients.

• Hyperglycemia management: Target glucose 140–180 mg/dL in critically ill; insulin infusion is preferred over sliding-scale; tight control (<110 mg/dL) increases hypoglycemia risk without mortality benefit.

• Lipid management: Use IV lipid emulsions (soybean, fish oil, or combination products); deliver 20–30% of total calories from fat to provide essential fatty acids (linoleic, α-linolenic acid) and prevent essential fatty acid deficiency (manifests as scaly dermatitis, alopecia, impaired wound healing); monitor triglycerides—if >400 mg/dL, reduce or hold lipids temporarily.

• Transition and weaning: As GI function returns, introduce enteral nutrition and taper TPN gradually; coordinate with speech pathology if swallowing assessment needed; fully transition to oral/enteral when meeting ≥60–75% of nutritional needs via GI route.

• Special populations:
• Renal failure: Reduce nitrogen load, restrict phosphate/potassium, adjust dextrose and lipids for fluid restriction.
• Hepatic failure: Lower amino acid content, consider BCAA-enriched formulations; monitor for encephalopathy.
• Diabetes: Higher insulin requirements; monitor glucose closely; may require separate insulin infusion.

• Catheter-related bloodstream infection (CRBSI): Most common serious complication; occurs in ~2–10% of central lines; gram-positive organisms (coagulase-negative staphylococci, Staphylococcus aureus) predominate; risk factors include prolong

• "If the gut works, use it": ASPEN and SCCM place enteral nutrition ahead of TPN whenever any absorptive surface is usable — including in severe acute pancreatitis, where enteral feeding is now preferred over bowel rest. Choosing TPN when a stem describes a functioning gut is the single most common wrong answer.
• Hypophosphatemia is the fingerprint of refeeding syndrome: insulin surge drives phosphate, potassium, and magnesium intracellularly, causing arrhythmia, rhabdomyolysis, hemolysis, and diaphragmatic weakness. Best next step is to slow or hold the infusion and replete electrolytes, not to stop nutrition entirely. Give thiamine before the dextrose load to avoid precipitating Wernicke encephalopathy.
• New fever, leukocytosis, or unexplained hyperglycemia in a patient stable on TPN = catheter-related bloodstream infection until proven otherwise. Next step is paired blood cultures drawn from the catheter and a peripheral vein; IDSA criteria use differential time to positivity. Coagulase-negative staphylococci predominate; Candida and S. aureus generally mandate catheter removal.
• Trace element syndromes are pure buzzword recall: zinc — perioral and acral bullous dermatitis with alopecia and poor wound healing (acrodermatitis enteropathica picture); copper — microcytic anemia with neutropenia plus myeloneuropathy mimicking B12 deficiency; selenium — cardiomyopathy; chromium — refractory hyperglycemia.
• Fat-free TPN over weeks produces essential fatty acid deficiency: scaly dermatitis, alopecia, thrombocytopenia, and an elevated triene:tetraene ratio.
• Abrupt discontinuation causes rebound hypoglycemia from persistent endogenous hyperinsulinemia — taper the infusion or bridge with dextrose-containing fluid.
• Excess dextrose raises the respiratory quotient and CO2 production, a classic reason a stem's patient fails ventilator weaning; the fix is reducing carbohydrate calories, not adding lipid indiscriminately.
• Cholestatic pattern with conjugated hyperbilirubinemia, plus biliary sludge and acalculous cholecystitis from gallbladder stasis; management is trophic enteral feeds, cycling the TPN, and limiting soybean-oil lipid load.
• Distractor to avoid: albumin and prealbumin are negative acute-phase reactants — low values in an inflamed patient reflect illness severity, not response to feeding.